![]() ![]() Take a look back at our Symposium and flash sessions presented at ECCMID 2021 ![]()
![]() Prof. Robert Krause Chair Medical University of Graz, Austria
![]() Prof. Emil Lesho ESCMID-appointed Chair Rochester Regional Health, New York, US
![]() Prof. Marco Falcone Italy
‘The evolving landscape of Gram-negative resistance’ ![]() Prof. Stefania Stefani Italy
‘Cefiderocol: What’s different about a siderophore cephalosporin?’ ![]() Prof. Ricard Ferrer Vall d’Hebron University Hospital Barcelona, Spain
‘APEKS & CREDIBLE-CR: Lessons learned from a Gram-negative focused clinical development programme’ ![]() ![]() Prof. Sarah Tschudin Sutter, MD MSc University Hospital Basel, Switzerland
‘Case report: Early clinical experience in the use of cefiderocol’ ![]() Prof. Aurélien Dinh Hôpital Raymond-Poincaré, Garches, APHP Paris Saclay Université, France
‘Case report: Prosthetic joint infection with Gram-negative multidrug-resistant organisms' ![]() Prof. Marco Falcone University of Pisa, Italy
‘Case report: Early clinical experience in the use of cefiderocol — Acinetobacter baumannii’ ![]() ![]() Prof. Bavaro Davide Fiore, MD University Hospital of Bari, Italy
‘Recurrent neurosurgical site infection by XDR Pseudomonas aeruginosa treated with cefiderocol’ ![]() Dr Temi Lampejo King’s College Hospital, London, UK
‘Cefiderocol for the treatment of a systemic infection due to carbapenemase-producing multidrug-resistant Klebsiella pneumoniae’ ![]() Dr Christopher Longshaw Shionogi B.V.,
‘In vitro activity of cefiderocol and comparator antimicrobials against carbapenem-non-susceptible Gram-negative isolates from Europe’
![]() Prof. Marco Falcone University of Pisa, Italy
‘Cefiderocol as Rescue Therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients’
‘Mechanisms of carbapenem resistance — Exploring the complexities’
Veeva ID (CH): PP-CH-FDC-0016 Fetcroja summary of product characteristics ![]() |
|